Cullinan Therapeutics Gross Profit

Cullinan Therapeutics (CGEM) currently reports a gross profit of $-79K as of June 2026. That compares with $-77K in the prior-year period — down 2.6% year over year. That is below the Healthcare sector average of $67B. Use the charts on this page to explore Cullinan Therapeutics's gross profit history and peer comparisons.

Cullinan Therapeutics's gross profit decreased from $-77K to $-79K — a 2.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cullinan Therapeutics's gross profit of $-79K is lower than the Healthcare sector average of $67B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Cullinan Therapeutics reported $-79K in gross profit as of June 2026. That compares with $-77K in the prior-year period — down 2.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $-79K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for Cullinan Therapeutics, and consider following CGEM for alerts when major investors trade the stock.